TickerFacts.

ImmunityBio, Inc. (IBRX): Cost of Revenue

Annual figures by period end, from SEC filings.

$753.0K
Year ended 2025-12-31
$1.09M
Trailing 12 months to 2026-06-30
2022-12-31: $02023-12-31: $02024-12-31: $02025-12-31: $753.0K$753.0K
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$753.0Kn/a2026-02-23, From 2025-01-01
2024-12-31$0n/a2026-02-23, From 2024-01-01
2023-12-31$0n/a2026-02-23, From 2023-01-01
2022-12-31$0n/a2025-03-03, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
ImmunityBio, Inc. (IBRX)2025-12-31$753.0Kn/a
Agenus Inc (AGEN)2025-12-31$1.02M+110.3%
Autolus Therapeutics plc (AUTL)2025-12-31$96.37M+746.3%
REGENXBIO Inc. (RGNX)2024-12-31$33.57M-9.8%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$70.95M+56.8%
Compugen Ltd (CGEN)2025-12-31$9.25M+16.7%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$70.0Kn/a
Vir Biotechnology, Inc. (VIR)2025-12-31$26.0K-96.9%
Champions Oncology, Inc. (CSBR)2026-04-30$30.90M+8.8%

Compare IBRX, AGEN, AUTL, RGNX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗